Akkermansia muciniphila for Insulin sensitivity / metabolic markers and Akkermansia muciniphila

Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.

Evidence brief

Akkermansia muciniphila for Insulin sensitivity / metabolic markers

Evidence grade C — One key trial

Grade C1 graded outcomerevised Jul 10, 2026

Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.

Compound or practice

Akkermansia muciniphila

A next-generation gut bacterium linked to metabolic health — one promising human trial, a lot still unknown.

Grade C1 graded outcomerevised Jul 10, 2026

A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.

Swap the two

Graded in both

Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.

OutcomeAkkermansia muciniphila for Insulin sensitivity / metabolic markersAkkermansia muciniphila
Insulin sensitivity / metabolic markers
Evidence grade CSmall effectlowOne key trial
Evidence grade CSmall effectlowOne key trial

Graded only in Akkermansia muciniphila for Insulin sensitivity / metabolic markers

None — every outcome it grades is graded in both.

Graded only in Akkermansia muciniphila

None — every outcome it grades is graded in both.

What each entry says about the other

  • Akkermansia muciniphila for Insulin sensitivity / metabolic markers’s entry · Goes with: Read the full Akkermansia muciniphila monograph

Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.